UnitedHealthcare Specialty Benefits Extends Coverage to ViziLite Plus, Zila's Oral...

UnitedHealthcare Specialty Benefits Extends Coverage to ViziLite Plus, Zila's Oral Cancer Screening Product

-- Early Detection Leads to Improved Health Outcomes, Lower
Medical Costs --
PHOENIX--(Business Wire)--
Zila, Inc. (NASDAQ:ZILA) today announced that UnitedHealthcare
Specialty Benefits (UHSB) began extending coverage for ViziLite(R)
Plus with TBlue(TM), Zila's innovative screening device for the early
detection of oral abnormalities that could lead to cancer.

"With UnitedHealthcare Specialty Benefits making oral cancer
screening with ViziLite Plus a benefit, more than 21 million lives are
now covered," said David Bethune, chairman and chief executive officer
of Zila. "UHSB is joining a growing list of premier national insurance
plans that provide coverage for ViziLite Plus, including Cigna,
Humana, Guardian and Safeguard, as well as a number of regional plans
and self-insured employers. Over time, this new coverage will
encourage more screening for oral cancer, and, in turn, enhance
ViziLite Plus sales. We believe insurance providers are extending
coverage of ViziLite Plus because early cancer detection leads to
improved health outcomes for patients and lower overall medical
costs."

"Given that 25% of oral cancers occur in people who do not smoke
and have no other behavioral risk factors, it is imperative that every
adult be screened at least once a year," said Mark Bride D.D.S., vice
president, Medical Affairs at Zila. "ViziLite Plus is a proven
technology used by thousands of dental offices across the United
States."

About Oral Cancer and ViziLite Plus

One American dies every hour of oral cancer. According to American
Cancer Society data, nearly as many women will be diagnosed with oral
cancer as with cervical cancer this year. The key to reducing the
impact of this disease is early detection.

ViziLite Plus is an oral screening technology that utilizes a
chemiluminescent light source (ViziLite) and a patented
pharmaceutical-grade vital tissue dye (TBlue). The ViziLite Plus exam
takes only minutes and is totally painless and non-invasive. Zila
began marketing the product through its direct sales force in the U.S.
in February 2007, in Canada in November 2007, and launched ViziLite
Plus in Europe in May 2008.

About UnitedHealthcare Specialty Benefits

UnitedHealthcare Specialty Benefits offers a broad array of
specialty benefits, including vision, dental, group and voluntary
insurance, worksite individual insurance and non-insurance programs.
UnitedHealthcare Specialty Benefits is a business unit of OptumHealth,
the health and wellness unit of UnitedHealth Group, Inc. (NYSE:UNH).
More information about OptumHealth can be found at
www.optumhealth.com/.

About Zila, Inc.

Zila, Inc., is a fully integrated oral diagnostic company
dedicated to the prevention, detection and treatment of oral cancer
and periodontal disease. ViziLite(R) Plus, the company's flagship
product for the early detection of oral abnormalities that could lead
to cancer, is the first and only adjunctive medical device cleared by
the FDA for use in a population at increased risk for oral cancer. In
addition, Zila designs, manufactures and markets a suite of
proprietary products sold exclusively and directly to dental
professionals for periodontal disease, including the Rota-dent(R)
Professional Powered Brush, the Pro-Select(R) Platinum ultrasonic
scaler and a portfolio of oral pharmaceutical products for both
in-office and home-care use.

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements are based largely on Zila's expectations or forecasts of
future events, can be affected by inaccurate assumptions and are
subject to various business risks and known and unknown uncertainties,
a number of which are beyond the Company's control. Therefore, actual
results could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or contribute
to such differences and could adversely affect revenue, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its fiscal
year ended July 31, 2007 and Form 10-Q for the quarter ended April 30,
2008.

For more information about the company and its products, visit
www.zila.com.

Investors:
PondelWilkinson Inc.
Robert Jaffe, 310-279-5969

Copyright Business Wire 2008